A dose- and time-controllable syngeneic animal model of breast cancer microcalcification

Fangbing Liu, Preeti Misra, Elaine P. Lunsford, Joanne T. Vannah, Yuxia Liu, Robert E. Lenkinski, John V. Frangioni

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The development of novel diagnostic agents for the detection of breast cancer microcalcifications requires a reliable animal model. Based on previous work from our group, we hypothesized that a single systemic injection of recombinant bone morphogenetic protein-2 (rBMP-2) could be used to create such a model. The cDNA encoding mature human BMP-2 was expressed in BL21(DE3) bacteria, purified to homogeneity, and refolded as a dimer. Bioactivity was confirmed using a C2C12 alkaline phosphatase assay. rBMP-2 was radiolabeled with 99mTc, and its biodistribution and clearance were quantified after both intravenous (IV) and intraperitoneal (IP) injection. Fischer 344 rats bearing syngeneic R3230 breast tumors received a single intraperitoneal injection of rBMP-2 at a specified dose. Tumor microcalcification was quantified over time using micro-single photon emission computed tomography (SPECT) and microcomputed tomography (CT). rBMP-2 could be expressed in E. coli at high levels, isolated at >95% purity, and refolded to a bioactive dimer. Beta-phase half-life was 30.5 min after IV administration and 47.6 min after IP administration. Renal excretion was the primary mode of clearance. A single IP injection of ≥50 μg rBMP-2 when tumors were not yet palpable resulted in dose-dependent microcalcification in 8 of 8 R3230 tumors. No calcification was found in control tumors or in normal tissues and organs of animals injected with rBMP-2. Tumor calcification increased progressively between weeks 2 and 4 post-rBMP-2 injection. A single IP injection of rBMP-2 in rats bearing a syngeneic breast cancer will produce dose-dependent and time-dependent microcalcifications. This animal model lays the foundation for the development of novel diagnostic radiotracers for breast cancer.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalBreast Cancer Research and Treatment
Volume122
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Calcinosis
Bone Morphogenetic Protein 2
Recombinant Proteins
Animal Models
Breast Neoplasms
Intraperitoneal Injections
Neoplasms
Animal Structures
X-Ray Microtomography
Injections
Inbred F344 Rats
Single-Photon Emission-Computed Tomography
Intravenous Injections
Intravenous Administration
Alkaline Phosphatase
Half-Life
Complementary DNA
Escherichia coli
Bacteria

Keywords

  • Animal models
  • BMP-2
  • Breast cancer
  • Micro-CT
  • Micro-SPECT/CT
  • Microcalcifications

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liu, F., Misra, P., Lunsford, E. P., Vannah, J. T., Liu, Y., Lenkinski, R. E., & Frangioni, J. V. (2010). A dose- and time-controllable syngeneic animal model of breast cancer microcalcification. Breast Cancer Research and Treatment, 122(1), 87-94. https://doi.org/10.1007/s10549-009-0535-6

A dose- and time-controllable syngeneic animal model of breast cancer microcalcification. / Liu, Fangbing; Misra, Preeti; Lunsford, Elaine P.; Vannah, Joanne T.; Liu, Yuxia; Lenkinski, Robert E.; Frangioni, John V.

In: Breast Cancer Research and Treatment, Vol. 122, No. 1, 07.2010, p. 87-94.

Research output: Contribution to journalArticle

Liu, F, Misra, P, Lunsford, EP, Vannah, JT, Liu, Y, Lenkinski, RE & Frangioni, JV 2010, 'A dose- and time-controllable syngeneic animal model of breast cancer microcalcification', Breast Cancer Research and Treatment, vol. 122, no. 1, pp. 87-94. https://doi.org/10.1007/s10549-009-0535-6
Liu, Fangbing ; Misra, Preeti ; Lunsford, Elaine P. ; Vannah, Joanne T. ; Liu, Yuxia ; Lenkinski, Robert E. ; Frangioni, John V. / A dose- and time-controllable syngeneic animal model of breast cancer microcalcification. In: Breast Cancer Research and Treatment. 2010 ; Vol. 122, No. 1. pp. 87-94.
@article{c8912add3ece49bb8fd5ce643b276680,
title = "A dose- and time-controllable syngeneic animal model of breast cancer microcalcification",
abstract = "The development of novel diagnostic agents for the detection of breast cancer microcalcifications requires a reliable animal model. Based on previous work from our group, we hypothesized that a single systemic injection of recombinant bone morphogenetic protein-2 (rBMP-2) could be used to create such a model. The cDNA encoding mature human BMP-2 was expressed in BL21(DE3) bacteria, purified to homogeneity, and refolded as a dimer. Bioactivity was confirmed using a C2C12 alkaline phosphatase assay. rBMP-2 was radiolabeled with 99mTc, and its biodistribution and clearance were quantified after both intravenous (IV) and intraperitoneal (IP) injection. Fischer 344 rats bearing syngeneic R3230 breast tumors received a single intraperitoneal injection of rBMP-2 at a specified dose. Tumor microcalcification was quantified over time using micro-single photon emission computed tomography (SPECT) and microcomputed tomography (CT). rBMP-2 could be expressed in E. coli at high levels, isolated at >95{\%} purity, and refolded to a bioactive dimer. Beta-phase half-life was 30.5 min after IV administration and 47.6 min after IP administration. Renal excretion was the primary mode of clearance. A single IP injection of ≥50 μg rBMP-2 when tumors were not yet palpable resulted in dose-dependent microcalcification in 8 of 8 R3230 tumors. No calcification was found in control tumors or in normal tissues and organs of animals injected with rBMP-2. Tumor calcification increased progressively between weeks 2 and 4 post-rBMP-2 injection. A single IP injection of rBMP-2 in rats bearing a syngeneic breast cancer will produce dose-dependent and time-dependent microcalcifications. This animal model lays the foundation for the development of novel diagnostic radiotracers for breast cancer.",
keywords = "Animal models, BMP-2, Breast cancer, Micro-CT, Micro-SPECT/CT, Microcalcifications",
author = "Fangbing Liu and Preeti Misra and Lunsford, {Elaine P.} and Vannah, {Joanne T.} and Yuxia Liu and Lenkinski, {Robert E.} and Frangioni, {John V.}",
year = "2010",
month = "7",
doi = "10.1007/s10549-009-0535-6",
language = "English (US)",
volume = "122",
pages = "87--94",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A dose- and time-controllable syngeneic animal model of breast cancer microcalcification

AU - Liu, Fangbing

AU - Misra, Preeti

AU - Lunsford, Elaine P.

AU - Vannah, Joanne T.

AU - Liu, Yuxia

AU - Lenkinski, Robert E.

AU - Frangioni, John V.

PY - 2010/7

Y1 - 2010/7

N2 - The development of novel diagnostic agents for the detection of breast cancer microcalcifications requires a reliable animal model. Based on previous work from our group, we hypothesized that a single systemic injection of recombinant bone morphogenetic protein-2 (rBMP-2) could be used to create such a model. The cDNA encoding mature human BMP-2 was expressed in BL21(DE3) bacteria, purified to homogeneity, and refolded as a dimer. Bioactivity was confirmed using a C2C12 alkaline phosphatase assay. rBMP-2 was radiolabeled with 99mTc, and its biodistribution and clearance were quantified after both intravenous (IV) and intraperitoneal (IP) injection. Fischer 344 rats bearing syngeneic R3230 breast tumors received a single intraperitoneal injection of rBMP-2 at a specified dose. Tumor microcalcification was quantified over time using micro-single photon emission computed tomography (SPECT) and microcomputed tomography (CT). rBMP-2 could be expressed in E. coli at high levels, isolated at >95% purity, and refolded to a bioactive dimer. Beta-phase half-life was 30.5 min after IV administration and 47.6 min after IP administration. Renal excretion was the primary mode of clearance. A single IP injection of ≥50 μg rBMP-2 when tumors were not yet palpable resulted in dose-dependent microcalcification in 8 of 8 R3230 tumors. No calcification was found in control tumors or in normal tissues and organs of animals injected with rBMP-2. Tumor calcification increased progressively between weeks 2 and 4 post-rBMP-2 injection. A single IP injection of rBMP-2 in rats bearing a syngeneic breast cancer will produce dose-dependent and time-dependent microcalcifications. This animal model lays the foundation for the development of novel diagnostic radiotracers for breast cancer.

AB - The development of novel diagnostic agents for the detection of breast cancer microcalcifications requires a reliable animal model. Based on previous work from our group, we hypothesized that a single systemic injection of recombinant bone morphogenetic protein-2 (rBMP-2) could be used to create such a model. The cDNA encoding mature human BMP-2 was expressed in BL21(DE3) bacteria, purified to homogeneity, and refolded as a dimer. Bioactivity was confirmed using a C2C12 alkaline phosphatase assay. rBMP-2 was radiolabeled with 99mTc, and its biodistribution and clearance were quantified after both intravenous (IV) and intraperitoneal (IP) injection. Fischer 344 rats bearing syngeneic R3230 breast tumors received a single intraperitoneal injection of rBMP-2 at a specified dose. Tumor microcalcification was quantified over time using micro-single photon emission computed tomography (SPECT) and microcomputed tomography (CT). rBMP-2 could be expressed in E. coli at high levels, isolated at >95% purity, and refolded to a bioactive dimer. Beta-phase half-life was 30.5 min after IV administration and 47.6 min after IP administration. Renal excretion was the primary mode of clearance. A single IP injection of ≥50 μg rBMP-2 when tumors were not yet palpable resulted in dose-dependent microcalcification in 8 of 8 R3230 tumors. No calcification was found in control tumors or in normal tissues and organs of animals injected with rBMP-2. Tumor calcification increased progressively between weeks 2 and 4 post-rBMP-2 injection. A single IP injection of rBMP-2 in rats bearing a syngeneic breast cancer will produce dose-dependent and time-dependent microcalcifications. This animal model lays the foundation for the development of novel diagnostic radiotracers for breast cancer.

KW - Animal models

KW - BMP-2

KW - Breast cancer

KW - Micro-CT

KW - Micro-SPECT/CT

KW - Microcalcifications

UR - http://www.scopus.com/inward/record.url?scp=77953545483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953545483&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0535-6

DO - 10.1007/s10549-009-0535-6

M3 - Article

C2 - 19760034

AN - SCOPUS:77953545483

VL - 122

SP - 87

EP - 94

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -